Her-2-neu expression and progression toward androgen independence in human prostate cancer

Journal of the National Cancer Institute

Volumn 92, Issue 23, 2000, Pages 1918-1925

  Signoretti, Sabina ^a   Montironi, Rodolfo ^b   Manola, Judith ^c   Altimari, Annalisa ^c   Tam, Carmen ^c   Bubley, Glenn ^d   Balk, Steven ^d   Thomas, George ^e   Kaplan, Irving ^d   Hlatky, Lynn ^c   Hahnfeldt, Philip ^c   Kantoff, Philip ^c   Loda, Massimo ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; COMPLEMENTARY RNA; DIAMINOBENZIDINE; DNA; GOSERELIN; GUANIDINE; HEMATOXYLIN; KI 67 ANTIGEN; MESSENGER RNA; NICKEL CHLORIDE; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P63; PROTEIN TYROSINE KINASE; SULFUR 35;

ARTICLE; BONE METASTASIS; CANCER HORMONE THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HORMONE DEPENDENCE; HORMONE INHIBITION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RNA ANALYSIS; STATISTICAL ANALYSIS; TUMOR GROWTH;

EID: 0034614108     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.23.1918     Document Type: Article

References (63)

1. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
2. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
3. Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma
4. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
5. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
6. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
7. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity
8. Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas
9. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer
10. Over-expression of epidermal growth factor receptor and c-erbB2/neu but not of int-2 genes in benign prostatic hyperplasia by means of semi-quantitative PCR
11. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma
12. Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma
13. Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: An immunohistochemical study
14. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia
15. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro
16. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer
17. An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer: Preliminary results and therapeutic implications
18. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma
19. New pieces to the prostate cancer puzzle [news]
20. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization
21. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma
22. Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas
23. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays
24. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer
25. Gains of the relative genomic content of erbB-1 and erbB-2 in prostate carcinoma and their association with metastasis
26. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
27. Histologic grading of prostate cancer: A prospective
28. P63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities
29. P63 is a prostate basal cell marker and is required for prostate development
30. Maximally selected chi square statistics
31. Heterogeneity of androgen receptor content in advanced prostate cancer
32. Specificity of Hercep Test in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system
33. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1
34. Individual comparisons by ranking methods
35. Multiple significance tests: The Bonferroni method
36. A distribution-free k-sample test against ordered alternatives
37. Exact significance testing to establish treatment equivalence with ordered categorical data
38. Pathological changes in prostate lesions after androgen manipulation
39. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process
40. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma
41. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens
42. Androgen receptors in endocrine-therapy-resistant human prostate cancer
43. Androgen receptor gene mutations in human prostate cancer
44. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone
45. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol
46. Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis
47. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
48. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
49. Activation of the human androgen receptor through a protein kinase A signaling pathway
50. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor
51. Activation of mitogen-activated protein kinase associated with prostate cancer progression
52. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer
53. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways
54. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells
55. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells
56. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors
57. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration
58. Hormonal control of apoptosis: The rat prostate gland as a model system
59. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models
60. Differential anti-tumor effects of targeting distinct epitopes of the Her-2/neu extracellular domain in xenograft models of prostate cancers
61. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis